{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:58:04Z","timestamp":1777492684202,"version":"3.51.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T00:00:00Z","timestamp":1172016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1038\/sj.npp.1301343","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T13:12:32Z","timestamp":1172063552000},"page":"2067-2073","source":"Crossref","is-referenced-by-count":17,"title":["Cannabinoids Influence Lipid\u2013Arachidonic Acid Pathways in Schizophrenia"],"prefix":"10.1038","volume":"32","author":[{"given":"Stefan","family":"Smesny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timm","family":"Rosburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kati","family":"Baur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinrich","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,2,21]]},"reference":[{"key":"BF1301343_CR1","volume-title":"The Scale for the Assessment of Negative Symptoms","author":"NC Andreasen","year":"1983","unstructured":"Andreasen NC (1983). The Scale for the Assessment of Negative Symptoms. The University of Iowa: Iowa."},{"key":"BF1301343_CR2","volume-title":"The Scale for the Assessment of Positive Symptoms","author":"NC Andreasen","year":"1984","unstructured":"Andreasen NC (1984). The Scale for the Assessment of Positive Symptoms. The University of Iowa: Iowa."},{"key":"BF1301343_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1600-0447.1989.tb10296.x","volume":"79","author":"S Andreasson","year":"1989","unstructured":"Andreasson S, Allebeck P, Rydberg U (1989). Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm county. Acta Psychiatr Scand 79: 505\u2013510.","journal-title":"Acta Psychiatr Scand"},{"key":"BF1301343_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1192\/bjp.184.2.110","volume":"184","author":"L Arseneault","year":"2004","unstructured":"Arseneault L, Cannon M, Witton J, Murray RM (2004). Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184: 110\u2013117.","journal-title":"Br J Psychiatry"},{"key":"BF1301343_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/0091-3057(91)90363-7","volume":"40","author":"CA Audette","year":"1991","unstructured":"Audette CA, Burstein SH, Doyle SA, Hunter SA (1991). G-protein mediation of cannabinoid-induced phospholipase activation. Pharmacol Biochem Behav 40: 559\u2013563.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF1301343_CR6","first-page":"79","volume":"37","author":"G Berger","year":"2003","unstructured":"Berger G, Wood S, McGorry P (2003). Incipient Neurovulnerability and Neuroprotection in Early Psychosis. Psychopharmacol Bull 37: 79\u2013101.","journal-title":"Psychopharmacol Bull"},{"key":"BF1301343_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1046\/j.1440-1614.2001.01021.x","volume":"36","author":"GE Berger","year":"2002","unstructured":"Berger GE, Wood SJ, Pantelis C, Velakoulis D, Wellard RM, McGorry PD (2002). Implications of lipid biology for the pathogenesis of schizophrenia. Aust NZ J Psychiatry 36: 355\u2013366.","journal-title":"Aust NZ J Psychiatry"},{"key":"BF1301343_CR8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/0006-2952(94)90163-5","volume":"48","author":"S Burstein","year":"1994","unstructured":"Burstein S, Budrow J, Debatis M, Hunter SA, Subramanian A (1994). Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem Pharmacol 48: 1253\u20131264.","journal-title":"Biochem Pharmacol"},{"key":"BF1301343_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0090-6980(00)00053-8","volume":"61","author":"SH Burstein","year":"2000","unstructured":"Burstein SH, Rossetti RG, Yagen B, Zurier RB (2000). Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 61: 29\u201341.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"BF1301343_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1192\/bjp.174.2.150","volume":"174","author":"R Cantwell","year":"1999","unstructured":"Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I et al (1999). Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 174: 150\u2013153.","journal-title":"Br J Psychiatry"},{"key":"BF1301343_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s004060050064","volume":"249","author":"D Caspari","year":"1999","unstructured":"Caspari D (1999). Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 249: 45\u201349.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BF1301343_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.biopsych.2005.01.026","volume":"57","author":"A Caspi","year":"2005","unstructured":"Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene \u00d7 environment interaction. Biol Psychiatry 57: 1117\u20131127.","journal-title":"Biol Psychiatry"},{"key":"BF1301343_CR13","first-page":"26","volume":"52","author":"JM Cleghorn","year":"1991","unstructured":"Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S (1991). Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J Clin Psychiatry 52: 26\u201330.","journal-title":"J Clin Psychiatry"},{"key":"BF1301343_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0024-3205(99)00287-8","volume":"65","author":"V Di Marzo","year":"1999","unstructured":"Di Marzo V (1999). Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci 65: 645\u2013655.","journal-title":"Life Sci"},{"key":"BF1301343_CR15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1046\/j.1471-4159.2000.0741627.x","volume":"74","author":"V Di Marzo","year":"2000","unstructured":"Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J et al (2000). Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 74: 1627\u20131635.","journal-title":"J Neurochem"},{"key":"BF1301343_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/0006-2952(73)90219-0","volume":"22","author":"JV Dingell","year":"1973","unstructured":"Dingell JV, Miller KW, Heath EC, Klausner HA (1973). The intracellular localization of 9-tetrahydrocannabinol in liver and its effects on drug metabolism in vitro. Biochem Pharmacol 22: 949\u2013958.","journal-title":"Biochem Pharmacol"},{"key":"BF1301343_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","volume":"57","author":"DC D'Souza","year":"2005","unstructured":"D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57: 594\u2013608.","journal-title":"Biol Psychiatry"},{"key":"BF1301343_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1192\/bjp.179.6.509","volume":"179","author":"PJ Duke","year":"2001","unstructured":"Duke PJ, Pantelis C, McPhillips MA, Barnes TR (2001). Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London. Br J Psychiatry 179: 509\u2013513.","journal-title":"Br J Psychiatry"},{"key":"BF1301343_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0006-3223(99)00092-X","volume":"47","author":"WS Fenton","year":"2000","unstructured":"Fenton WS, Hibbeln J, Knable M (2000). Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 47: 18\u201321.","journal-title":"Biol Psychiatry"},{"key":"BF1301343_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1360-0443.2005.01070.x","volume":"100","author":"RF Ferdinand","year":"2005","unstructured":"Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC (2005). Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100: 612\u2013618.","journal-title":"Addiction"},{"key":"BF1301343_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3109\/15622970109027496","volume":"2","author":"H Fukuzako","year":"2001","unstructured":"Fukuzako H (2001). Neurochemical investigation of the schizophrenic brain by in vivo phosphorus magnetic resonance spectroscopy. World J Biol Psychiatry 2: 70\u201382.","journal-title":"World J Biol Psychiatry"},{"key":"BF1301343_CR22","first-page":"495","volume":"28","author":"WF Gattaz","year":"1990","unstructured":"Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK (1990). Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry 28: 495\u2013501.","journal-title":"Biol Psychiatry"},{"key":"BF1301343_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0006-3223(87)90164-8","volume":"22","author":"WF Gattaz","year":"1987","unstructured":"Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen PK (1987). Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry 22: 421\u2013426.","journal-title":"Biol Psychiatry"},{"key":"BF1301343_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0920-9964(94)00060-L","volume":"16","author":"WF Gattaz","year":"1995","unstructured":"Gattaz WF, Schmitt A, Maras A (1995). Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 16: 1\u20136.","journal-title":"Schizophr Res"},{"key":"BF1301343_CR25","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","volume":"29","author":"A Giuffrida","year":"2004","unstructured":"Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J et al (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108\u20132114.","journal-title":"Neuropsychopharmacology"},{"key":"BF1301343_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0278-5846(01)00162-2","volume":"25","author":"M Glass","year":"2001","unstructured":"Glass M (2001). The role of cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 25: 743\u2013765.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BF1301343_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0952-3278(96)90139-8","volume":"55","author":"AI Glen","year":"1996","unstructured":"Glen AI, Cooper SJ, Rybakowski J, Vaddadi K, Brayshaw N, Horrobin DF (1996). Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids 55: 9\u201315.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"BF1301343_CR28","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1176\/appi.ajp.160.4.636","volume":"160","author":"II Gottesman","year":"2003","unstructured":"Gottesman II, Gould TD (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636\u2013645.","journal-title":"Am J Psychiatry"},{"key":"BF1301343_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.eurpsy.2004.09.013","volume":"20","author":"A Grech","year":"2005","unstructured":"Grech A, van Os J, Jones PB, Lewis SW, Murray RM (2005). Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 20: 349\u2013353.","journal-title":"Eur Psychiatry"},{"key":"BF1301343_CR30","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/j.1440-1614.2000.00736.x","volume":"34","author":"M Hambrecht","year":"2000","unstructured":"Hambrecht M, Hafner H (2000). Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust NZ J Psychiatry 34: 468\u2013475.","journal-title":"Aust NZ J Psychiatry"},{"key":"BF1301343_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/bmj.38267.664086.63","volume":"330","author":"C Henquet","year":"2005","unstructured":"Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU et al (2005a). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330: 11.","journal-title":"BMJ"},{"key":"BF1301343_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/schbul\/sbi027","volume":"31","author":"C Henquet","year":"2005","unstructured":"Henquet C, Murray R, Linszen D, van Os J (2005b). The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31: 608\u2013612.","journal-title":"Schizophr Bull"},{"key":"BF1301343_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0006-3223(96)00112-6","volume":"41","author":"CJ Hudson","year":"1997","unstructured":"Hudson CJ, Lin A, Cogan S, Cashman F, Warsh JJ (1997). The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia? Biol Psychiatry 41: 507\u2013513.","journal-title":"Biol Psychiatry"},{"key":"BF1301343_CR34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/BF00966122","volume":"11","author":"SA Hunter","year":"1986","unstructured":"Hunter SA, Burstein S, Renzulli L (1986). Effects of cannabinoids on the activities of mouse brain lipases. Neurochem Res 11: 1273\u20131288.","journal-title":"Neurochem Res"},{"key":"BF1301343_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1192\/bjp.178.2.116","volume":"178","author":"A Johns","year":"2001","unstructured":"Johns A (2001). Psychiatric effects of cannabis. Br J Psychiatry 178: 116\u2013122.","journal-title":"Br J Psychiatry"},{"key":"BF1301343_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0091-3057(79)90111-4","volume":"11","author":"A Kalofoutis","year":"1979","unstructured":"Kalofoutis A, Koutselinis A (1979). Changes induced by hashish constituents on human erythrocyte phospholipids. Pharmacol Biochem Behav 11: 383\u2013385.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF1301343_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1600-0773.1978.tb02239.x","volume":"43","author":"A Kalofoutis","year":"1978","unstructured":"Kalofoutis A, Koutselinis A, Dionyssiou-Asteriou A, Miras C (1978). The significance of lymphocyte lipid changes after smoking hashish. Acta Pharmacol Toxicol 43: 81\u201385.","journal-title":"Acta Pharmacol Toxicol"},{"key":"BF1301343_CR38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0091-3057(80)90151-3","volume":"12","author":"A Kalofoutis","year":"1980","unstructured":"Kalofoutis A, Lekakis J, Koutselinis A (1980). Effects of delta 9-THC on human platelet phospholipids. Pharmacol Biochem Behav 12: 697\u2013699.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF1301343_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/026990598122674","volume":"12","author":"CP Kaplan","year":"1998","unstructured":"Kaplan CP, Miner ME, Mervis L, Newton H, McGregor JM, Goodman JH (1998). Interpretive risks: the use of the hopkins symptom checklist 90-revised (SCL 90-R) with brain tumour patients. Brain Inj 12: 199\u2013205.","journal-title":"Brain Inj"},{"key":"BF1301343_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0006-3223(00)00940-9","volume":"48","author":"MS Keshavan","year":"2000","unstructured":"Keshavan MS, Stanley JA, Pettegrew JW (2000). Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings\u2014part II. Biol Psychiatry 48: 369\u2013380.","journal-title":"Biol Psychiatry"},{"key":"BF1301343_CR41","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1176\/appi.ajp.158.6.958","volume":"158","author":"S Klemm","year":"2001","unstructured":"Klemm S, Rzanny R, Riehemann S, Volz HP, Schmidt B, Gerhard UJ et al (2001). Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia. Am J Psychiatry 158: 958\u2013960.","journal-title":"Am J Psychiatry"},{"key":"BF1301343_CR42","first-page":"304","volume":"81","author":"FM Leweke","year":"2006","unstructured":"Leweke FM, Schreiber D, Koethe D, Nolden BM, Gerth CW, Neatby MA et al (2006). Endocannabinoids in patients with first-episode schizophrenia and schizophreniform psychosis: relation to cannabis use. Schizophr Res 81: 304\u2013305.","journal-title":"Schizophr Res"},{"key":"BF1301343_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0920-9964(94)00053-B","volume":"15","author":"PK McGuire","year":"1995","unstructured":"McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM (1995). Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 15: 277\u2013281.","journal-title":"Schizophr Res"},{"key":"BF1301343_CR44","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1192\/bjp.168.5.612","volume":"168","author":"PR Menezes","year":"1996","unstructured":"Menezes PR, Johnson S, Thornicroft G, Marshall J, Prosser D, Bebbington P et al (1996). Drug and alcohol problems among individuals with severe mental illness in south London. Br J Psychiatry 168: 612\u2013619.","journal-title":"Br J Psychiatry"},{"key":"BF1301343_CR45","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.plefa.2003.08.013","volume":"69","author":"E Messamore","year":"2003","unstructured":"Messamore E (2003). Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 69: 413\u2013419.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"BF1301343_CR46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychol Rep 10: 799\u2013812.","journal-title":"Psychol Rep"},{"key":"BF1301343_CR47","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1136\/bmj.325.7374.1195","volume":"325","author":"GC Patton","year":"2002","unstructured":"Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W (2002). Cannabis use and mental health in young people: cohort study. BMJ 325: 1195\u20131198.","journal-title":"BMJ"},{"key":"BF1301343_CR48","first-page":"257","volume":"81S","author":"BK Puri","year":"2006","unstructured":"Puri BK, Richardson AD, Counsell SJ, Ward DS, Bustos MG, Hamilton G et al (2006). Negative correlation between the volumetric niacin response and cerebral inorganic phosphate in male patients with schizophrenia who have seriously and dangerously violently offended: a 31-phosphorus magnetic resonance spectroscopy study. Schizophrenia Res 81S: 257.","journal-title":"Schizophrenia Res"},{"key":"BF1301343_CR49","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.plefa.2003.08.009","volume":"69","author":"RD Reddy","year":"2003","unstructured":"Reddy RD, Yao JK (2003). Environmental factors and membrane polyunsaturated fatty acids in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 69: 385\u2013391.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"BF1301343_CR50","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/oxfordjournals.schbul.a007140","volume":"30","author":"RD Reddy","year":"2004","unstructured":"Reddy RD, Keshavan MS, Yao JK (2004). Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 30: 901\u2013911.","journal-title":"Schizophr Bull"},{"key":"BF1301343_CR51","first-page":"547","volume":"40","author":"M Reichman","year":"1991","unstructured":"Reichman M, Nen W, Hokin LE (1991). Delta 9-tetrahydrocannabinol inhibits arachidonic acid acylation of phospholipids and triacylglycerols in guinea pig cerebral cortex slices. Mol Pharmacol 40: 547\u2013555.","journal-title":"Mol Pharmacol"},{"key":"BF1301343_CR52","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1046\/j.1360-0443.1998.9368375.x","volume":"93","author":"D Reilly","year":"1998","unstructured":"Reilly D, Didcott P, Swift W, Hall W (1998). Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 93: 837\u2013846.","journal-title":"Addiction"},{"key":"BF1301343_CR53","first-page":"122","volume":"81","author":"A Rosa","year":"2006","unstructured":"Rosa A, Henquet C, Krabbendam L, Papiol S, Fananas L, Drukker M et al (2006). Experimental study of COMT VAL158MET moderation of cannabis-induced effects on psychosis and cognition. Schizophrenia Res 81: 122.","journal-title":"Schizophrenia Res"},{"key":"BF1301343_CR54","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1001\/archpsyc.1997.01830170113015","volume":"54","author":"BM Ross","year":"1997","unstructured":"Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ (1997). Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Arch Gen Psychiatry 54: 487\u2013494.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1301343_CR55","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1139\/y72-173","volume":"50","author":"P Seeman","year":"1972","unstructured":"Seeman P, Chau-Wong M, Moyyen S (1972). The membrane binding of morphine, diphenylhydantoin, and tetrahydrocannabinol. Can J Physiol Pharmacol 50: 1193\u20131200.","journal-title":"Can J Physiol Pharmacol"},{"key":"BF1301343_CR56","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1034\/j.1600-0447.2001.00452.x","volume":"104","author":"S Sevy","year":"2001","unstructured":"Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R et al (2001). Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 104: 367\u2013374.","journal-title":"Acta Psychiatr Scand"},{"key":"BF1301343_CR57","first-page":"163","volume":"43","author":"SH Shah","year":"2000","unstructured":"Shah SH, Vankar GK, Peet M, Ramchand CN (2000). Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr Res 43: 163\u2013164.","journal-title":"Schizophr Res"},{"key":"BF1301343_CR58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0920-9964(00)00132-8","volume":"48","author":"PD Skosnik","year":"2001","unstructured":"Skosnik PD, Spatz-Glenn L, Park S (2001). Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res 48: 83\u201392.","journal-title":"Schizophr Res"},{"key":"BF1301343_CR59","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0074-7742(04)59010-4","volume-title":"International Review of Neurobiology: Disordersof Synaptic Plasticity and Schizophrenia","author":"S Smesny","year":"2004","unstructured":"Smesny S (2004b). Prostaglandin mediated signaling in schizophrenia. In: Smythies J (ed). International Review of Neurobiology: Disordersof Synaptic Plasticity and Schizophrenia. Elsevier Academic Press: San Diego, London. pp 255\u2013266."},{"key":"BF1301343_CR60","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0022-3956(03)00006-2","volume":"37","author":"S Smesny","year":"2003","unstructured":"Smesny S, Berger G, Rosburg T, Riemann S, Riehemann S, McGorry P et al (2003). Potential use of the topical niacin skin test in early psychosis\u2014a combined approach using optical reflection spectroscopy and a descriptive rating scale. J Psychiatr Res 37: 237\u2013247.","journal-title":"J Psychiatr Res"},{"key":"BF1301343_CR61","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biopsych.2004.11.018","volume":"57","author":"S Smesny","year":"2005","unstructured":"Smesny S, Kinder D, Willhardt I, Rosburg T, Lasch J, Berger G et al (2005a). Increased calcium-independent phospholipase A2-activity in first episode but not in chronic schizophrenia\u2014further evidence of sustained lipid damage at the onset of disorder. Biol Psychiatry 57: 399\u2013405.","journal-title":"Biol Psychiatry"},{"key":"BF1301343_CR62","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1515\/bmte.2001.46.10.280","volume":"46","author":"S Smesny","year":"2001","unstructured":"Smesny S, Riemann S, Riehemann S, Bellemann ME, Sauer H (2001). Quantitative measurement of induced skin flushing by optical reflection spectroscopy\u2014method and clinical application. Biomed Technic 46: 280\u2013286.","journal-title":"Biomed Technic"},{"key":"BF1301343_CR63","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jpsychires.2004.01.007","volume":"38","author":"S Smesny","year":"2004","unstructured":"Smesny S, Rosburg T, Klemm S, Riemann S, Baur K, Rudolph N et al (2004a). The influence of age and gender on niacin skin test results\u2014implications for the use as a biochemical marker in schizophrenia. J Psychiatr Res 38: 537\u2013543.","journal-title":"J Psychiatr Res"},{"key":"BF1301343_CR64","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.plefa.2005.02.007","volume":"72","author":"S Smesny","year":"2005","unstructured":"Smesny S, Rosburg T, Riemann S, Baur K, Rudolph N, Berger G et al (2005b). Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. Prostaglandins Leukot Essent Fatty Acids 72: 393\u2013402.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"BF1301343_CR65","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0006-3223(00)00949-5","volume":"48","author":"JA Stanley","year":"2000","unstructured":"Stanley JA, Pettegrew JW, Keshavan MS (2000). Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings\u2014part I. Biol Psychiatry 48: 357\u2013368.","journal-title":"Biol Psychiatry"},{"key":"BF1301343_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0920-9964(02)00281-5","volume":"61","author":"H Tavares","year":"2003","unstructured":"Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF (2003). Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res 61: 1\u20136.","journal-title":"Schizophr Res"},{"key":"BF1301343_CR67","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/j.1360-0443.2005.01083.x","volume":"100","author":"J van Os","year":"2005","unstructured":"van Os J, Henquet C, Stefanis N (2005). Cannabis-related psychosis and the gene\u2013environment interaction: comments on Ferdinand et al, 2005. Addiction 100: 874\u2013875.","journal-title":"Addiction"},{"key":"BF1301343_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1017\/S0033291702006384","volume":"33","author":"H Verdoux","year":"2003","unstructured":"Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD (2003). Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med 33: 23\u201332.","journal-title":"Psychol Med"},{"key":"BF1301343_CR69","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0920-9964(99)00031-6","volume":"40","author":"MC Waldo","year":"1999","unstructured":"Waldo MC (1999). Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophr Res 40: 49\u201353.","journal-title":"Schizophr Res"},{"key":"BF1301343_CR70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1054\/plef.2000.0193","volume":"63","author":"PE Ward","year":"2000","unstructured":"Ward PE (2000). Potential diagnostic aids for abnormal fatty acid metabolism in a range of neurodevelopmental disorders. Prostaglandins Leukot Essent Fatty Acids 63: 65\u201368.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"BF1301343_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0014-5793(95)00027-7","volume":"359","author":"M Wartmann","year":"1995","unstructured":"Wartmann M, Campbell D, Subramanian A, Burstein SH, Davis RJ (1995). The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett 359: 133\u2013136.","journal-title":"FEBS Lett"},{"key":"BF1301343_CR72","volume-title":"Strukturiertes Klinisches Interview f\u00fcr DSM-IV","author":"H-U Wittchen","year":"1997","unstructured":"Wittchen H-U, Fydrich T, Zaudig M (1997). Strukturiertes Klinisches Interview f\u00fcr DSM-IV. Hogrefe Verlag: G\u00f6ttingen."},{"key":"BF1301343_CR73","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/bmj.325.7374.1199","volume":"325","author":"S Zammit","year":"2002","unstructured":"Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325: 1199.","journal-title":"BMJ"},{"key":"BF1301343_CR74","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.2004.00843.x","volume":"99","author":"S Zammit","year":"2004","unstructured":"Zammit S, Lewis G (2004). Exploring the relationship between cannabis use and psychosis. Addiction 99: 1353\u20131355.","journal-title":"Addiction"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1301343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1301343","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1301343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T06:53:51Z","timestamp":1684220031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1301343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,21]]},"references-count":74,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["BF1301343"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1301343","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,21]]}}}